

Edgar Filing: I TRAX INC - Form 424B3

I TRAX INC
Form 424B3
December 20, 2004

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-114604

PROSPECTUS SUPPLEMENT
(To Prospectus dated December 1, 2004)

5,043,177 SHARES

I-TRAX

[LOGO OMITTED]

COMMON STOCK

The shareholders named in this prospectus supplement are offering up to 5,043,177 shares of our common stock. We will not receive any of the proceeds from the shares of common stock sold by the selling shareholders. In connection with this offering, the selling shareholders will pay fees to Oppenheimer & Co. Inc., as exclusive placement agent. See "Plan of Distribution" on page S-3 of this prospectus supplement for more information regarding this arrangement.

Our common stock is listed on the American Stock Exchange under the symbol "DMX." On December 16, 2004, the closing price for our common stock was \$1.55 per share.

Investing in our common stock involves significant risks, which are described under the caption "Risk Factors" beginning on page 8 of the accompanying prospectus and the caption "Risk Factor" on page S-2 of this prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

	Per share	Maximum offering amount
Public offering price	\$1.250	\$6,303,971
Placement agent fee	\$0.075	\$ 378,238
Proceeds to the selling shareholders	\$1.175	\$5,925,733

We estimate the total expenses of this offering payable by us, excluding the placement agent fee, will be approximately \$55,000. In addition, we have agreed to pay the fees and expenses of counsel for the placement agent in an amount not to exceed \$35,000 in the aggregate. The placement agent is not required to sell any specific number or dollar amount of the shares of common stock offered by the selling shareholders in this offering, but will use its best efforts to sell the shares of common stock offered. The offering will end on or prior to December 22, 2004. Pursuant to an escrow agreement among us, the selling shareholders, the placement agent and an escrow agent, certain funds received in payment for the shares sold in this offering will be deposited into an interest-bearing escrow account and held until we, the selling shareholders and the placement agent notify the escrow agent that the offering has closed,

Edgar Filing: I TRAX INC - Form 424B3

indicating the date on which the shares are to be delivered to the purchasers and the proceeds are to be delivered to the selling shareholders. Because there is no minimum offering price required as a condition to closing in this offering, the actual public offering price, placement agent fee and proceeds to the selling shareholders, if any, in this offering are not presently determinable and may be substantially less than the maximum offering amounts set forth above.

OPPENHEIMER & CO.

DECEMBER 17, 2004

TABLE OF CONTENTS

Prospectus Supplement

Selling Security Holders.....
Risk Factor.....
Plan of Distribution.....
Legal Matters.....

Accompanying Prospectus

I-trax, Inc.....
Risk Factors.....
Statement Regarding Forward-Looking Information.....
Cautionary Note.....
Market for Our Common Stock.....
Use of Proceeds.....
Selling Security Holders.....
Plan of Distribution.....
Available Information.....
Incorporation of Certain Documents by Reference.....
Legal Matters.....
Experts.....

This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus are part of a resale registration statement that we filed with the Securities and Exchange Commission. Such resale registration statement also includes a separate prospectus covering the resale of up to an additional 10,676,094 shares of our common stock. Under the resale registration process, certain of our shareholders may offer from time to time up to 27,326,530 shares of our common stock, including 800,000 shares that we may issue as dividends on outstanding shares of our Series A Convertible Preferred Stock (together with such additional number of shares of common stock as may be issued or issuable by reason of any stock split, stock dividend or similar

Edgar Filing: I TRAX INC - Form 424B3

transaction involving our common stock), of which this offering is a part.

In this prospectus supplement, we provide you with specific information about the shares of our common stock that the selling shareholders are selling in this offering. This prospectus supplement and the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus include important information about us, our selling shareholders, our common stock being offered and other information you should know before investing. This prospectus supplement also adds, updates, and changes information contained in the accompanying prospectus. You should read both this prospectus supplement and the accompanying prospectus as well as the additional information described under "Available Information" before investing in shares of our common stock.

You should rely only on information contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide you with information that is different. The selling shareholders are offering to sell and seeking offers to buy shares of our common stock only in jurisdictions where such offers and sales are permitted. The information contained in this prospectus supplement and the accompanying prospectus is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock.

i

SELLING SECURITY HOLDERS

The following table sets forth the shareholders offering shares of our common stock pursuant to this prospectus supplement and information as of December 17, 2004 (except as otherwise noted) regarding beneficial ownership of shares of our common stock prior to and after such offering by those shareholders. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission.

Name of Selling Shareholder	Number of Shares of Common Stock Beneficially Owned Before Offering			Number of Shares Common Stock Offered for Sale
	Common Stock (1)	Common Stock Underlying Series A Convertible Preferred Stock (2)	Common Stock Issuable as Dividend on Series A Convertible Preferred Stock (3)	
Warburg, Pincus Ventures, L.P.	4,148,461	623,595	64,053	3,674,870

Edgar Filing: I TRAX INC - Form 424B3

CHD Investors, LLC 1,544,646 232,190 23,849 1,368,307

- (1) Includes the following number of shares of common stock that were issued to an escrow agent in connection with our acquisition of CHD Meridian Healthcare and will be issued to the selling shareholders listed below upon the occurrence of certain conditions:

Selling Shareholder -----	No. of Shares -----
Warburg, Pincus Ventures, L.P.	1,161,239
CHD Investors, LLC	432,378

The selling shareholders have voting power but not dispositive power with respect to the shares held in escrow.

- (2) The selling shareholders listed in the table are expected to convert their Series A Convertible Preferred Stock upon the closing of the offering under this prospectus supplement.
- (3) Our Series A Convertible Preferred Stock accrues dividends on the original issue price of \$25 per share at the rate of 8% per annum. The dividends are payable upon conversion of the Series A Convertible Preferred Stock into common stock in additional shares of common stock or, subject to the consent of our senior secured lender, in cash. The shares listed in this column represent the number of shares of common stock issuable as accrued dividends on outstanding shares of Series A Convertible Preferred Stock as of December 16, 2004.

Joel Ackerman, a representative of Warburg, Pincus Ventures, L.P., served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

Brad Cooper, a representative of CHD Investors, LLC, served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

S-1

Voting and Dispositive Power

The following individuals have voting and dispositive power with respect to the shares of I-trax common stock offered under this prospectus supplement:

Name of Selling Shareholder -----	Individual or Individuals Who Exercise Voting and Dispositive Power -----
Warburg, Pincus Ventures, L.P.	Warburg, Pincus & Co., the general partner, and Warburg Pincus LLC, manager.
CHD	Investors, LLC

Edgar Filing: I TRAX INC - Form 424B3

The ultimate corporate general partner has such voting and dispositive power.

RISK FACTOR

In addition to the risk factors discussed under the caption "Risk Factors" beginning on page 8 in the accompanying prospectus, you should also consider the following additional risk when investing in our common stock.

In the event that the amendment to our 2001 Equity Compensation Plan is not approved by our shareholders, certain of our option holders may have a claim against us.

During the third quarter of 2004, we granted options to acquire 1,742,000 shares of our common stock that we have concluded were not validly granted and, therefore, are not outstanding because, among other reasons, the grant did not comply with Internal Revenue Code regulations applicable to grants of incentive stock options and the terms of our 2001 Equity Compensation Plan. Our Board of Directors subsequently amended our 2001 Equity Compensation Plan to increase the number of shares available for grant under the Plan, which amendment is subject to shareholder approval. We expect our Board of Directors to grant options to purchase these shares and possibly other options to acquire additional shares of our common stock under the amended 2001 Equity Compensation Plan. However, there can be no assurance, that our shareholders will approve such amendment prior to the time our Board grants such options or at all. In the event our shareholders do not approve the amendment, the options issued under the Plan subsequent to the Board's approval of the amendment will be invalid. As a result, the persons granted those options may have claims against us. Such claims could adversely impact our business and financial condition.

S-2

PLAN OF DISTRIBUTION

The selling shareholders are offering the shares of our common stock through a placement agent. Subject to the terms and conditions contained in the placement agent agreement dated December 17, 2004, Oppenheimer & Co. Inc. has agreed to act as the exclusive placement agent for the sale of up to 5,043,177 shares of our common stock by the selling shareholders. The placement agent is not purchasing or selling any shares by this prospectus supplement or accompanying prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of shares, but has agreed to use best efforts to arrange for the sale of all 5,043,177 shares.

The placement agent agreement provides that the obligations of the placement agent and the investors are subject to certain conditions precedent, including the absence of any material adverse change in our business and the receipt of certain opinions, letters and certificates from us, the selling shareholders, our counsel, counsel for the selling shareholders and our independent auditors.

Confirmations and definitive prospectuses will be distributed to all investors who agree to purchase shares of our common stock pursuant to this prospectus supplement, informing investors of the closing date as to such

Edgar Filing: I TRAX INC - Form 424B3

shares. We currently anticipate that closing of the sale of 5,043,177 shares of common stock will take place on or about December 22, 2004. Investors will also be informed of the date and manner in which they must transmit the purchase price for their shares.

On the scheduled closing date, the following will occur:

- o the selling shareholders will receive funds in the amount of the aggregate purchase price; and
- o Oppenheimer & Co. Inc. will receive the placement agent's fee in accordance with the terms of the placement agent agreement.

The selling shareholders will pay the placement agent an aggregate commission equal to 6% of the gross proceeds of the sale of shares of common stock sold by the selling shareholders in the offering and we will pay the fees and expenses of counsel for the placement agent in an amount not to exceed \$35,000 in the aggregate. In no event will the total amount of compensation paid to the placement agent and other securities brokers and dealers upon completion of this offering exceed 8% of the maximum gross proceeds of the offering. The estimated offering expenses payable by us are approximately \$90,000, which includes legal, accounting and printing costs and various other fees associated with registering and listing the shares of common stock.

Pursuant to the placement agent agreement, we and the selling shareholders have agreed to indemnify the placement agent against certain liabilities, including liabilities under the Securities Act of 1933, as amended. We and the selling shareholders have also agreed to contribute to payments the placement agent may be required to make in respect of such liabilities.

Our executive officers and directors and a key employee have agreed to certain lock-up provisions with regard to future sales of our common stock for a period ending on the date it is finally determined if any shares of our securities will be issued pursuant to the earn-out provision of the former CHD Meridian shareholders, as set forth in the placement agent agreement. In addition, we have agreed, subject to customary exceptions, that for a period of 90 days after the offering we will not issue any shares of our securities at a purchase price that is less than the purchase price paid for the shares sold by the selling shareholders in this offering, as set forth in the placement agent agreement.

The placement agent agreement with Oppenheimer & Co. Inc. will be included as an exhibit to our Current Report on Form 8-K that will be filed with the Securities and Exchange Commission in connection with the consummation of this offering.

The transfer agent for our common stock is StockTrans, Inc.

Our common stock is listed on the American Stock Exchange under the symbol "DMX."

S-3

LEGAL MATTERS

The validity of the shares of our common stock offered by this prospectus supplement and the accompanying prospectus will be passed upon for us

Edgar Filing: I TRAX INC - Form 424B3

by our Vice President, General Counsel and Secretary. Brown Raysman Millstein Felder & Steiner LLP in New York, New York is acting as counsel for the placement agent in connection with various legal matters relating to the shares of common stock offered by this prospectus supplement and the accompanying prospectus.

S-4

PROSPECTUS

I-TRAX, INC.

[LOGO OMITTED]

15,850,436

SHARES OF

COMMON STOCK

This prospectus relates to the offer and sale from time to time of the following shares held by the selling shareholders:

- o up to 13,851,550 shares of our common stock; and
- o up to 1,998,886 shares of our common stock issuable upon the conversion of outstanding Series A Convertible Preferred Stock.

The shares covered by this prospectus will be offered for resale through one or more registered broker-dealers.

The prices at which selling shareholders may sell the shares will be determined by the prevailing market price for the shares or in negotiated transactions. We will not receive any of the proceeds from the sale of the shares.

Our common stock is listed on the American Stock Exchange under the symbol "DMX." On November 26, 2004, the closing price for our common stock was \$1.42.

This prospectus is part of a registration statement, which also includes a separate prospectus covering the resale of up to an additional 10,676,094 shares of our common stock.

Investing in our common stock involves risks, which are described in the "Risk Factors" section beginning on page 8 of this prospectus.

Edgar Filing: I TRAX INC - Form 424B3

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus is December 1, 2004

TABLE OF CONTENTS

I-trax, Inc.....	3
Risk Factors.....	8
Statement Regarding Forward-Looking Information.....	18
Cautionary Note.....	18
Market for Our Common Stock.....	19
Use of Proceeds.....	19
Selling Security Holders.....	20
Plan of Distribution.....	23
Available Information.....	25
Incorporation of Certain Documents by Reference.....	25
Legal Matters.....	26
Experts.....	26

-2-

I-TRAX, INC.

Overview

I-trax is an integrated health and productivity management company formed by the merger on March 19, 2004 of I-trax, Inc. and Meridian Occupational Healthcare Associates, Inc., which does business as CHD Meridian Healthcare.

We offer two categories of services that can be integrated or blended as necessary or appropriate based on each client's needs. The first category includes on-site health related services such as occupational health, primary care, corporate health, and pharmacy, which were historically offered by CHD Meridian Healthcare. We believe we are the nation's largest provider of on-site corporate health management services. The second category includes personalized health management programs, which were historically offered by I-trax.

Our services are designed to allow employers to contract directly for a wide range of employee healthcare needs. We can deliver these services at or near the client's work site by opening, staffing and managing a clinic or pharmacy dedicated to the client and its employees, or remotely by using the Internet and our state-of-the-art Care Communication Center staffed with trained nurses and other healthcare professionals who are available 24 hours per day, 7 days per week. Our array of services provides each client with flexibility to meet its specific pharmacy, primary care, occupational health, corporate health, wellness, lifestyle management or disease management needs.

We provide services to approximately 150 clients, including automotive

Edgar Filing: I TRAX INC - Form 424B3

and automotive parts manufacturers, consumer products manufacturers, large financial institutions, health plans, integrated delivery networks, and third party administrators. We currently operate approximately 168 on-site facilities in 32 states. Our client retention rate is high due to strong client relationships that are supported by the critical nature of our services, the benefits achieved by employer and employee constituents, and the utilization of multi-year service contracts.

Our Services

Occupational Health Services

We provide professional staffing and management of on-site health facilities that address the occupational health, workers' compensation injuries, and minor illness needs of the employer's workforce. These programs are designed to operate across the entire array of occupational health regulatory environments and emphasize work-related injury cost-reduction, treatment, medical surveillance or testing, disability management, case management, return-to-work coordination, medical community relations or oversight, on-site physical therapy and injury prevention, and ergonomic assessment and intervention. Our health programs improve compliance with treatment protocols and drug formularies, enhance employee productivity, and allow for greater employer control of occupational health costs. We currently operate 81 occupational health facilities.

Primary Care Services

We operate employer-sponsored health centers designed to integrate with the employer's existing healthcare plans. In such arrangements, employers contract with us directly for primary care health services and in the process regain control of costs, quality and access. Generally, each of our health centers services a single employer and offers health management programs addressing the primary care needs of the employee base, including optometry services and prevention and disease management programs. Clients may combine our health centers with a dedicated pharmacy. We also offer customized solutions in network management and absence management, including non-work related case management and disability management. Our physicians, nurses, and other staff are dedicated to the customer's employee population, allowing employees, retirees, and their dependents to receive cost-effective, high quality, accessible and convenient care. We currently operate 18 primary care centers.

-3-

Pharmacy Services

We operate employer-sponsored pharmacies that offer prescription services exclusively to the client's covered population. A client may also combine our pharmacy with a dedicated primary care center. By leveraging prescription volume across our client base and procuring pharmaceuticals as a captive class of trade, we purchase products at considerable savings for our clients, thus significantly and positively affecting what we understand is one of our clients' fastest-growing healthcare cost categories. Our pharmacy services also use sophisticated information technologies. These technologies may be integrated with each client's existing pharmacy management programs and plans, and improve employees' prescription fulfillment convenience. We currently operate 24 pharmacies.

Corporate Health Services

We offer custom designed workplace programs that combine preventative

Edgar Filing: I TRAX INC - Form 424B3

care, occupational health, medical surveillance and testing, travel medicine and health education to non-industrial clients that do not experience significant physical injury rates, but nonetheless maintain large workforces with general and specialized medical needs. Clients for which we provide corporate health services include financial service, advertising and consulting firms. We currently operate 45 corporate healthcare facilities.

Personalized Health Management Programs

Our personalized health management programs are designed to deliver lifestyle and wellness management, and disease and risk reduction interventions to a client's entire population, across multiple locations and irrespective of population size. Using predictive science, sophisticated, proprietary computer software, clinical expertise, and personal care coordination, we enable our clients to provide their employees and dependents with a more cohesive and efficient system of healthcare. We use a unified data platform to allow all caregivers to share records, thus enabling our clients to provide effective coordination of care. We believe that by facilitating real-time secure communication between our client, the patient, the doctor, the care coordinator and the insurer our health management solutions reduce costs and enable improved delivery of care.

Predictive Science. Our programs incorporate predictive science to analyze our client's medical claims and pharmacy and clinical data to predict future healthcare costs, which of those costs are avoidable, the health conditions that will drive those costs, and the people within our client's populations who are at risk for those conditions. Armed with this information, we tailor our programs to help the client achieve better care, savings and other desired results.

Technology Solutions. Our technology utilizes a single data platform--Medicive(R) Medical Enterprise Data System--a proprietary software architecture developed to collect, store, sort, retrieve and analyze a broad range of information used in the healthcare industry. Our web accessible software includes portals for key stakeholders in the care delivery process--consumers, physicians and care managers--and permit real-time sharing of information and support the adherence to our health and disease intervention programs.

Interventions and Clinical Expertise. Our programs include personalized health and disease interventions for individuals who suffer from, or are at high risk for, active or chronic disease and tailored programs for individuals who are at low risk. Depending on the individual's level of risk, our custom-tailored interventions include self-help programs available through the web or person-assisted programs administered through our Care Communication Center. All interventions include lifestyle and risk reduction programs that follow evidence-based clinical guidelines to optimize health, fitness, productivity, and quality of life.

Care Communication Center. Our Care Communication Center is staffed with trained nurses and other healthcare professionals 24 hours per day, 7 days per week. Through the Center, we effect targeted interventions to achieve the goals of our programs. The Center helps each member or employee of our client make informed decisions about his or her health and provides ongoing support for those with chronic diseases. Our demand management and nurse triage services incorporate nationally recognized, evidence-based clinical guidelines to increase compliance by caregivers and consumers with best practices.

Edgar Filing: I TRAX INC - Form 424B3

Our Client Contracts

Our client contracts for on-site clinics and pharmacies are typically for an initial term of three to five years and renew automatically in the absence of notice to the contrary. Under these contracts, we typically provide services to our clients' employees, dependents and retirees, although arrangements vary depending on the contract. We charge these clients for our services on a "cost plus" basis to provide care to these individuals.

Similar to contracts for on-site clinics and pharmacies, contracts covering our personalized health management programs are typically for an initial term of three to five years and renew automatically in the absence of notice to the contrary. Under these contracts, we typically charge our clients a per member or per employee per month fee, which increases with a corresponding increase in the level of service we provide. Basic personalized health management programs provide inbound telephone access to a nurse or healthcare professional for triage or health information, 24 hours per day, 7 days per week, for employees, health plan members and, in many instances, dependents. Enhanced programs, which we introduced in October 2003, provide inbound and outbound contacts by telephone, mail and e-mail and electronic health information and tools. Some clients also engage us to provide to their members, employees and dependents custom disease management programs to target individuals with a specific disease or who are at high risk for a specific disease. We charge additional fees for individuals that elect to enroll in our disease management programs. Our personalized health management contracts also allow risk-sharing. These contracts provide for an incentive payment and/or fee refund if we fail to achieve or exceed, as appropriate, a targeted percentage reduction in our client's healthcare costs.

Our Strategy

Our business strategy is to improve the health status of employee populations and manage the claim trend experienced by employers and employees, self-insured employers and government agencies. These groups often seek programs that promote health, manage disease and disability, and complement existing health initiatives and benefits. Self-insured employers and government agencies invest in such health programs because they reduce later need for critical care and related costs, increase productivity, reduce absenteeism, improve health status of both active employees and retirees, and reduce overall costs.

We believe that our programs offer a complete solution to meet this need. We service each segment of a self-insured employer's population to achieve the desired clinical and financial outcomes. Our on-site programs reduce healthcare costs of the populations that use our facilities. Complementing those services, our personalized health management programs improve the health of each client's entire population, achieving the same result. We believe that the combination of our on-site services and personalized health management solutions responds to a specific and frequent request of large employers for a comprehensive range of health management services. We also believe that we can offer our on-site clients the value added benefit of our personalized health management programs.

Finally, our programs offer our clients multiple services and price entry points to meet their budget restrictions and specific needs. We believe that this available menu of services helps shorten our sales cycle and provides us with an opportunity to build a more comprehensive program as the relationship grows with each client over time.

Risks Inherent in Our Business

As we pursue the opportunities described in this report, we face

Edgar Filing: I TRAX INC - Form 424B3

numerous and significant challenges specific to our company and the healthcare industry in general. Challenges specific to our company include:

- o We must integrate I-trax's and CHD Meridian Healthcare's services, which prior to the merger focused on different delivery methods within the corporate health management solutions market. If we are not able to integrate our services successfully, we will not realize the benefits we anticipated from the merger.
- o The sales cycle for our services is complex, unpredictable and has generally ranged from 3 to 24 months from initial contact to contract signing. The time it takes to implement our services is also

-5-

difficult to predict and has lasted as long as 18 months from contract execution to the commencement of live operation. During the sales cycle and the implementation period, we may expend substantial time, effort and money preparing contract proposals, negotiating the contract and implementing the solution without receiving any related revenue.

- o We are competing with numerous companies offering services that are similar to ours. Such competition could reduce the number of new clients we obtain and could cause us to reduce our pricing and, consequently, our gross margins.
- o Implementation and delivery of our personalized health management programs is highly dependent on data about individuals to whom we provide care supplied to us by our clients, and on our information technology systems that process such data when we receive it. If we do not receive timely and accurate data from our clients, or if our information technology systems do not process such data accurately, we may not be able to fulfill our client contracts, which could have a material adverse effect on our business, results of operations and financial condition.
- o Our personalized health management programs are dependent on efficient deployment, implementation, and scalability of our software technology. To date, we have implemented our software technology for only a relatively few covered lives. We must continue to develop our software technology to provide the scalability and new functionality necessary to accommodate the greater number of covered lives we expect as we add new clients. If we fail to respond to these requirements, our ability to process new business could be slowed, which ultimately could have a material adverse effect on our business, results of operations and financial condition.
- o Our revenue depends on the contractual relationships we establish and maintain with our clients. Some of our contracts provide for early termination. Other contracts may be terminated by our clients because of their deteriorating financial condition. No assurances can be given that the results of contract restructurings and possible terminations at or prior to renewal would not have a material negative impact on our results of operations and financial condition.

Edgar Filing: I TRAX INC - Form 424B3

Challenges specific to our industry include:

- o In recent years, healthcare costs have grown significantly and as a result the healthcare industry is under significant price pressure. Although this has increased interest in our services because they are designed to contain costs, we are nonetheless subject to this general trend. It is conceivable that new and potential clients will continue to pressure us to reduce our prices and if we do, our revenues growth will slow and our gross margins will decrease.
- o We are subject to extensive state and Federal regulation, which grows more complex each year. As such, compliance efforts have also increased in complexity. We may need additional resources to assure compliance, which will increase our expenses and decrease our gross margins.

Corporate Information

General

Our principal executive offices are located at 4 Hillman Drive, Suite 130, Chadds Ford, Pennsylvania 19317. Our telephone number is (610) 459-2405 and our fax number is (610) 459-4705. We maintain a website located at <http://www.i-trax.com>. Information contained on our website is not part of this prospectus.

We make available our annual reports on Form 10-KSB, quarterly reports on Form 10-QSB and current reports on Form 8-K, as well as any amendments to the foregoing, free of charge on our website as soon as reasonably practicable after they have been filed with the SEC. For a detailed description of our business, you should read these reports and the other filings we make with the SEC which are incorporated by reference in this prospectus.

-6-

Corporate History

I-trax was incorporated in Delaware on September 15, 2000 at the direction of the Board of Directors of I-trax Health Management Solutions, Inc., I-trax's then parent company. On February 5, 2001, I-trax became the holding company of I-trax Health Management at the closing of a reorganization pursuant to Section 251(g) of Delaware General Corporation Law. At the effective time of the reorganization, all of the stockholders of I-trax Health Management became the stockholders of I-trax and I-trax Health Management became a wholly owned subsidiary of I-trax. Further, all outstanding shares of I-trax Health Management were converted into shares of I-trax in a non-taxable transaction.

The holding company structure has allowed us greater flexibility in our operations and expansion and diversification plans, including in the acquisitions of Meridian Occupational Healthcare Associates, Inc. and WellComm Group, Inc.

I-trax acquired WellComm effective February 6, 2002. In the acquisition, we paid the WellComm stockholders approximately \$2,200,000 in cash and 1,488,000 shares of our common stock. We also issued to each of two senior officers of WellComm options to acquire 56,000 shares of our common stock at a nominal exercise price. Because the acquisition was structured as a merger, we also assume all of WellComm's liabilities, which equaled approximately \$775,000.

Edgar Filing: I TRAX INC - Form 424B3

We funded this acquisition by selling a 6% convertible senior debenture in the aggregate principal amount of \$2,000,000 to Palladin Opportunity Fund LLC. We also issued Palladin a warrant to purchase up to 307,692 shares of our common stock. As of March 19, 2004, Palladin has converted all amounts outstanding under the debenture into common stock and has exercised the warrant in full at the conversion price and exercise price of \$1.75 per share.

We acquired CHD Meridian Healthcare on March 19, 2004. Under the merger agreement, we delivered to CHD Meridian Healthcare stockholders 10,000,000 shares of I-trax common stock, 400,000 shares of I-trax Series A Convertible Preferred Stock, each of which is convertible into 10 shares of I-trax common stock, and paid \$25,508,000 in cash. I-trax obtained the cash portion of the merger consideration by selling 1,000,000 shares of Series A Convertible Preferred Stock at a purchase price of \$25.00 per share for gross proceeds of \$25,000,000, and by borrowing \$12,000,000 on a new senior secured debt facility from a national lender.

In the merger, I-trax assumed all of CHD Meridian Healthcare's liabilities, which equaled approximately \$20,000,000.

Immediately following the closing of the merger, I-trax redeemed from former CHD Meridian Healthcare stockholders that participated in the merger, pro rata, an aggregate of 200,000 shares of Series A Convertible Preferred Stock at their original issue price of \$25.00 per share.

Further, under the terms of the merger, if CHD Meridian Healthcare, continuing its operations following the closing of the merger as a subsidiary of I-trax, achieves calendar 2004 milestones for earnings before interest, taxes, depreciation and amortization, or EBITDA, additional shares of common stock will be payable as follows: If EBITDA equals or exceeds \$8,100,000, the number of such additional shares of common stock payable will be 3,473,280; the number of such shares increases proportionately up to a maximum of 3,859,200 shares if EBITDA equals or exceeds \$9,000,000. Any escrowed shares that are not released will be returned to I-trax for cancellation. The escrowed shares are not deemed outstanding for accounting purposes until released. Based upon CHD Meridian Healthcare's results of operations as of September 30, 2004, management believes that CHD Meridian Healthcare will achieve at least the minimum EBITDA target set forth in the merger agreement.

Finally, under the merger agreement and the related financing documents, we are required to register for resale the shares of common stock issued in the merger and issuable upon conversion of shares of Series A Convertible Preferred Stock issued in the merger and in the related financing.

-7-

RISK FACTORS

You should carefully consider the following risks in evaluating I-trax and its business. Our business, financial condition and results of operations could be materially and adversely affected by each of these risks. Such an adverse effect could cause the market price of our common stock to decline, and you could lose all or part of your investment.

Risk Related to I-trax

If we are not able to implement our business strategy of deploying our integrated services effectively to existing and new clients, we will not be able to grow our revenue.

Edgar Filing: I TRAX INC - Form 424B3

Although we believe that there is significant demand for the our services and products in the corporate healthcare market, there are many reasons why we may be unable to execute our business strategy, including our possible inability to:

- o deploy our integrated services and solutions on a large scale;
- o attract a sufficiently large number of self-insured employers to subscribe for our services and software applications;
- o increase awareness of our brand;
- o strengthen user loyalty;
- o develop and improve our services and solutions;
- o continue to develop and upgrade our services and software solutions; and
- o attract, retain and motivate qualified personnel.

Our inability to achieve the above goals will impact our revenue growth.

Our credit facility contains certain covenants and financial tests that limit the way we conduct business.

Our senior secured credit facility contains certain covenants and financial tests that limit the way we conduct business. Financial tests include a covenant measuring the ratio of our funded indebtedness to earnings before income, taxes, depreciation and amortization, the ratio of our funded indebtedness to capitalization, and our fixed charges coverage ratio. The consolidated net worth covenant requires us to maintain our stockholders' equity at 90% of the level as of December 31, 2005. Other covenants restrict our ability to incur certain debt and complete mergers and dispose of assets.

We were not in compliance with certain financial tests as of June 30, 2004 and amended the credit facility to address non-compliance on August 12, 2004. We subsequently amended the credit facility on October 27, 2004. As of the date of this prospectus, we are in compliance with all covenants. At November 1, 2004, \$10,500,000 was outstanding under the credit facility.

The covenants and financial tests in the credit facility may prevent us from accessing working capital, competing effectively or taking advantage of new business opportunities. If we cannot comply with these covenants or meet these ratios and other tests, it could result in a default under our credit facility, and unless we are able to negotiate an amendment, forbearance or waiver, we could be required to repay all amounts then outstanding, which could have a material adverse effect on our business, results of operations and financial condition.

Borrowings under our credit facility also are secured by liens on substantially all of our assets and the assets of our subsidiaries. If we are in default under one of these credit facilities, the lender could foreclose upon all

Edgar Filing: I TRAX INC - Form 424B3

or substantially all of our assets and the assets of our subsidiaries. We cannot assure you that we will generate sufficient cash flow to repay our indebtedness, and we further cannot assure you that, if the need arises, we will be able to obtain additional financing or to refinance our indebtedness on terms acceptable to us, if at all. Any such failure to obtain financing could have a material adverse effect on our business, results of operations and financial condition.

Increasing competition for contracts to establish and manage employer-dedicated pharmacies and clinics increases the likelihood that we may lose business to our competitors.

CHD Meridian Healthcare pioneered the field of employer-dedicated pharmacies and primary care clinics. Although CHD Meridian Healthcare has always faced competition from other methods by which business enterprises can arrange and pay for healthcare services for their employees, until recently we rarely experienced face-to-face bidding for a contract to manage a particular employer's pharmacy or clinic. We have recently begun to see direct competition for employer-dedicated pharmacy management contracts, including from Caremark and Express Scripts. We expect this competition will increase over time. We believe that we have certain advantages in facing such competition, including our experience and know-how. However, some of our competitors and potential competitors, including prescription benefit management companies, with revenues in the multiple billions of dollars, are substantially bigger than we are. We believe that the potential market for employer-dedicated pharmacies is large enough for us to meet our growth plans despite increasing competition, but there are no assurances that we will in fact be able to do so. Our ability to maintain existing clients, expand services to existing clients, add new clients so as to meet our growth objectives, and maintain attractive pricing for our services, will depend on the interplay among overall growth in the use of employer-dedicated facilities, entry of new competitors into our business, and our success or failure in maintaining our market position as against these new entrants.

In addition to this increasing head-to-head competition for contracts to establish and manage employer-dedicated facilities, we expect to continue to face competition for large employers' healthcare budget from other kinds of enterprises, including pharmacy benefit managers, health insurers, managed health care plans, and retail pharmacy chains.

Loss of advantageous pharmaceutical pricing could adversely affect our income and the value we provide to our clients.

We receive favorable pricing from pharmaceutical manufacturers as a result of our class of trade designation, which means that we only sell pharmaceutical products to our clients' employees, dependents and retirees. We also receive rebates from pharmaceutical manufacturers for driving market share to preferred products. The benefit of favorable pricing is generally passed on to our clients under the terms of client contracts. In the last few years, retail pharmacies have brought legal cases against pharmaceutical manufacturers challenging class of trade designations as unlawful price discrimination under the Robinson-Patman Act. Although these challenges have generally failed, there remains a possibility that we could lose the benefit of this favorable pricing, either due to a legal challenge or to a change in policies of the pharmaceutical manufacturers. Such a loss would diminish the value that we can provide to our clients and, therefore, would make our services less attractive. We also receive volume performance incentives from our pharmaceutical wholesaler which directly affect our revenue and the loss of which could adversely affect our income.

Our business involves exposure to professional liability claims, and a failure to manage effectively our professional liability risks could expose us to unexpected expenses, which would result in losses.

Edgar Filing: I TRAX INC - Form 424B3

Under the terms of our contracts to manage employer sponsored clinics or pharmacies, we must procure professional liability insurance covering the operations of that clinic or pharmacy. We also typically agree to indemnify our clients against vicarious professional liability claims arising out of acts or omissions of healthcare providers working at the clinics and pharmacies we manage. Further, under the terms of our services agreements with affiliated professional corporations, we are contractually obligated to procure malpractice insurance on behalf of the professional corporations and their employed physicians and typically absorb such claims as are subject to the policy self-insured retention limit (which is explained below) or above the policy limit. Finally, there also exists the possibility of vicarious professional liability claims being made directly against us. As a result of these contractual arrangements, we routinely incur significant expenses arising out of professional liability claims. If we fail to

-9-

manage the professional liability claims and associated risk effectively, we may sustain losses beyond our historic trend.

Certain of our past professional liability insurance policy years were insured by two insurance companies that are now either insolvent or under regulatory supervision. As a result, we are effectively partially uninsured for those periods. We have established reserves in connection with the six pending claims from such policy years. Although we believe such reserves are reasonable based on our historic loss experience, there is no assurance that these reserves will be sufficient to pay all judgments or settlements. In addition, our current professional liability insurance provides for self-insured retention of \$500,000. A self-insured retention is the amount that we have agreed to assume responsibility for under our insurance policy as if we are the insurer subject to the terms of the policy and related regulatory scheme. This means that we are, effectively, partially uninsured against a variety of claims that may arise from other years. We maintain a layer of excess insurance that begins with losses in excess of \$1,000,000 per claim, including for the years in which our primary insurer is insolvent. We have reserved for projected future professional liability expenses based on our operations to date. These reserves, however, could prove inadequate, the size of our ultimate uninsured liability could exceed our established reserves and we will sustain losses.

Our professional liability insurance policies are written on a "claims-made" basis, meaning that they cover only claims made during the policy period, and not events that occur during the policy period but result in a claim after the expiration of the policy. With this insurance strategy, we must renew or replace coverage each year in order to have coverage for prior years' operations. Availability and cost of such coverage are subject to market conditions, which can fluctuate significantly.

We have established a subsidiary insurance company, which subjects us to additional regulatory requirements and once operating, will subject us to the risks associated with the insurance business.

We have established as a wholly owned subsidiary insurance company and began operating it in the second quarter of 2004 to insure our professional liability exposure. We believe this approach will enhance our ability to manage malpractice exposure and stabilize insurance costs. Operating an insurance subsidiary, however, represents additional risk to our operations, including a potential perception among our existing and potential clients that we are not adequately insured. We have hired a manager and have engaged an actuarial consulting firm for the insurance subsidiary. When we commence its operations,

Edgar Filing: I TRAX INC - Form 424B3

we will be subject to the risks associated with any insurance business, which include investment risk relating to the performance of our invested assets set aside as reserves for future claims, the uncertainty of making actuarial estimates of projected future professional liability losses, and loss adjustment expenses. Failure to make an adequate return on our investments, to maintain the principal of invested funds, or to estimate future losses and loss adjustment expenses accurately, could cause us to sustain losses. Also, maintaining the insurance subsidiary has exposed us to substantial additional regulatory requirements, with attendant risks if we fail to comply with applicable regulations.

We may be unable to integrate successfully our operations and realize the full cost savings we anticipate from the merger.

The merger of CHD Meridian Healthcare and I-trax involves the integration of two companies that have previously operated independently and focused on different delivery methods within the corporate health management solutions market. The difficulties of combining the merged companies' operations include:

- o integrating complementary businesses under centralized management efficiently;
- o coordinating geographically separated organizations;
- o integrating personnel with diverse business backgrounds; and
- o combining different corporate cultures.

The process of integrating operations could cause an interruption of, or loss of momentum in, the activities of I-trax or CHD Meridian Healthcare's businesses or the loss of key personnel. The diversion of management's

-10-

attention and any delays or difficulties encountered in connection with the integration of the merged companies' operations could have an adverse effect on the business, results of operations or financial condition of the merged companies.

Among the factors considered by the CHD Meridian Healthcare and the I-trax boards of directors in connection with their respective approvals of the merger were the opportunities for reduction of operating costs and improvements in operating efficiencies and other financial synergies that could result from the merger. We cannot give any assurance that these savings will be realized, or if realized, will be realized within the time periods contemplated by management.

If our clients do not provide us accurate data, or if we do not process such data accurately, we may not be able to fulfill our client contracts.

Implementation and delivery of our personalized health management programs is highly dependent on data about individuals to whom we provide care supplied to us by our clients, and on our information technology systems that process such data when we receive it. If we do not receive timely and accurate data from our clients, or if our information technology systems do not process such data accurately, we may not be able to fulfill our client contracts, which could have a material adverse effect on our business, results of operations and financial condition.

Edgar Filing: I TRAX INC - Form 424B3

If we lose key employees or fail to recruit and retain other skilled employees, we may not be able to continue our growth.

Our business greatly depends on, among others, Frank A. Martin, chairman, chief executive officer and director, Haywood D. Cochrane, Jr., vice chairman and director, and Charles D. (Chip) Phillips, executive vice president and chief operating officer. If we cannot retain any one of these individuals, we will lose employees with considerable knowledge of our business, which could significantly reduce our ability to compete and succeed in the future.

We maintain employment agreements with Messrs. Martin and Cochrane. Mr. Martin's employment agreement expires in December 2004. Mr. Cochrane's agreements expire in January 2005. Each employment agreement may be terminated by us with or without cause and by the applicable executive with or without good reason. We maintain a \$5,000,000 key-man life insurance policy on Mr. Martin.

Our future success also depends on our ability to attract, retain and motivate highly skilled employees. As we secure new contracts and implement our services and products, we will need to hire additional personnel in all operational areas. We may be unable, however, to attract, assimilate or retain such highly qualified personnel. Although we have not experienced such difficulties in the recent past, we may do so in the future, especially if the labor markets continue to tighten. If we cannot attract new personnel or retain and motivate current personnel, the service level we provide to our clients may suffer, which may cause us to lose clients and revenue.

Our sales cycle is long and complex, which may slow our growth.

The corporate health management business is growing rapidly and has many entrants. Further, although each entrant may define its service as corporate health management, the details of the services among the entrants are quite different. Because the services offered are complex, require clients to incur significant upfront costs and there are significant variations in the offered services by many vendors, potential clients take a long time to evaluate and purchase such services, lengthening our sales cycle. Further, the sales and implementation process for our services and software applications is lengthy, involves a significant technical evaluation and requires our clients to commit a great deal of time and money. Finally, the sale and implementation of our services are subject to delays due to our clients' internal budgets and procedures for approving large capital expenditures and deploying new services and software applications within their organizations. The sales cycle for our solutions, therefore, is unpredictable and has generally ranged from 3 to 24 months from initial contact to contract signing. The time it takes to implement our services is also difficult to predict and has lasted as long as 18 months from contract execution to the commencement of live operation. During the sales cycle and the implementation period, we may expend substantial time, effort and money preparing contract proposals, negotiating the contract and implementing the solution without receiving any related revenue.

-11-

Deterioration of the financial health of our clients, many of which are large U.S. manufacturing enterprises, may impair our business volume and collections.

Edgar Filing: I TRAX INC - Form 424B3

An adverse trend in one or more U.S. manufacturing industries could lead to plant closings or layoffs that could eliminate or reduce the need for some of our employer-dedicated healthcare facilities. Also, if our client becomes insolvent, we may not be able to recover outstanding accounts receivable owed by that client, and may suffer premature contract termination.

Our professional liability insurance is written on a "claims-made" basis. This means that we are protected from malpractice claims only if the company that insured us at the time of the alleged "occurrence" is the same company at the time the claim is filed in court. If it is not, we will not have coverage. To continue coverage in such circumstances, we must obtain "tail" insurance coverage or continue to purchase insurance written on a "claims made" basis. We typically charge our clients for tail insurance coverage when the contract terminates. If a client is insolvent when the contract terminates, however, we may not be able to recoup the cost of tail insurance coverage, or other costs related to that facility's shutdown. We already experienced this in the case of Bethlehem Steel and National Steel, two clients for which we managed several facilities when these clients became debtors in Federal bankruptcy proceedings. This resulted in difficulty in collecting some amounts due to us, and generated claims against us of approximately \$1,000,000 in the aggregate for repayment of allegedly preferential transfers previously received from the client. We have settled approximately half of such claims for significantly less than originally demanded. Nonetheless, because of the risks associated with client insolvency, and the concentration of CHD Meridian Healthcare's client base, our business is to some extent dependent on the continued health of U.S. manufacturing industries.

We are dependent on software technologies and as such subject to frequent change and risks associated with Internet viruses and outages, which could destroy the information we maintain or prevent our clients from accessing important information.

Our web-based software applications that form the backbone of our personalized health management programs depend on the continuous, reliable and secure operation of Internet servers and related hardware and software. Numerous viruses and outages on the Internet could cause outages of our applications from time to time. To the extent that our services are interrupted, our users will be inconvenienced and our reputation may be diminished. If access to our system becomes unavailable at a critical time, users could allege we are liable, which could depress our stock price, cause significant negative publicity and possibly lead to litigation. Although our computer and communications hardware is protected by physical and software safeguards, it is still vulnerable to fire, storm, flood, power loss, telecommunications failures, physical or software break-ins and similar events. We do not have 100% redundancy for all of our computer and telecommunications facilities. A catastrophic event could have a significant negative effect on our business, results of operations, and financial condition.

We also depend on third parties to provide certain of our clients with Internet and online services necessary for access to our servers. It is possible that our clients will experience difficulties with Internet and other online services due to system failures, including failures unrelated to our systems. Any sustained disruption in Internet access provided by third parties could have a material adverse effect on our business, results of operations and financial condition.

Finally, we retain confidential healthcare information on our servers. It is, therefore, important that our facilities and infrastructure remain secure and are perceived by clients to be secure. Although we operate our software applications from a secure facility managed by a reputable third party, our

Edgar Filing: I TRAX INC - Form 424B3

infrastructure may be vulnerable to physical or virtual break-ins, computer viruses, programming errors or similar disruptive problems. A material security breach could damage our reputation or result in liability to us.

We are dependent on our ability to deploy and implement our software technologies efficiently.

Our personalized health management programs are dependent on efficient deployment, implementation, and scalability of our software technology. To date, we have implemented our software technology for relatively few clients. We must continue to develop our software technology to provide the scalability and new functionality

-12-

necessary to accommodate the greater number of clients we expect. If we fail to respond to these requirements, our ability to process new business could be slowed, which ultimately could have a material adverse effect on our business, results of operations and financial condition. We are addressing these requirements by adding software development personnel, and expect to spend in 2005 approximately \$500,000 in excess of our 2004 software development budget.

We may be sued and incur losses if we provide inaccurate health information on our website or inadvertently disclose confidential health information to unauthorized users.

Because users of our website will access health content and services relating to a medical condition they may have or may distribute our content to others, third parties may sue us for defamation, negligence, copyright or trademark infringement, personal injury or other matters. We could also become liable if confidential information is disclosed inappropriately. These types of claims have been brought, sometimes successfully, against online services in the past. Others could also sue us for the content and services that will be accessible from our website through links to other websites or through content and materials that may be posted by our users in chat rooms or bulletin boards. Any such liability will have a material adverse effect on our reputation and our business, results of operations or financial position.

We may be unable to compete successfully against companies offering other disease management products, which will impair our revenue growth.

Many healthcare companies are offering disease management services and healthcare focused software solutions. Further, a vast number of Internet sites offer healthcare content, products and services. In addition, traditional healthcare providers compete for consumers' attention both through traditional means as well as through new Internet initiatives. Although we believe our technology-enabled service solutions are unique and better than our competitors', we compete for customers with numerous other businesses.

We believe our competitors include the following:

- o Disease management and care enhancement companies, such as American Healthways, LifeMasters, Matria Healthcare, CorSolutions, SHPS Healthcare Services, and Health Dialog.
- o Wellness companies, such as StayWell, HealthMedia, Harris Health Trends, and Impact Health.
- o On-site healthcare providers, such as Comprehensive Health

Edgar Filing: I TRAX INC - Form 424B3

Services, MedCor and Whole Health Management.

- o Pharmacy benefit management companies, such as Caremark and Express Scripts.
- o Regional occupational health clinics and providers.

Many of these potential competitors are likely to enjoy substantial competitive advantages compared to us, including:

- o greater name recognition and larger marketing budgets and resources;
- o larger customer and user bases;
- o larger production and technical staffs;
- o substantially greater financial, technical and other resources; and
- o a wider array of online products and services.

-13-

To be competitive, we must continue to enhance our products and services as well as our sales and marketing channels. If we do not, we will not be able to grow our revenue.

If other companies develop intellectual property identical or similar to ours, we will lose what we believe to be our competitive advantage.

Our intellectual property is important to our business. We rely on a combination of copyright, trademark and trade secret laws, confidentiality procedures and contractual provisions to protect our intellectual property. Our efforts to protect our intellectual property may not be adequate. Our competitors may independently develop similar technology or duplicate our products or services. Unauthorized parties may infringe upon or misappropriate our products, services or proprietary information. In addition, the laws of some foreign countries do not protect proprietary rights as well as the laws of the United States do, and the global nature of the Internet makes it difficult to control the ultimate destination of our products and services. In the future, litigation may be necessary to enforce our intellectual property rights or to determine the validity and scope of the proprietary rights of others. Any such litigation would probably be time-consuming and costly. We could be subject to intellectual property infringement claims as the number of our competitors grows and the content and functionality of software applications and services overlap with competitive offerings. Defending against these claims, even if not meritorious, could divert our attention from operating our company. If we become liable to third parties for infringing their intellectual property rights, we could be required to pay a substantial damage award and forced to develop noninfringing technology, obtain a license or cease selling the applications that contain the infringing technology. We may be unable to develop noninfringing technology or obtain a license on commercially reasonable terms, or at all. We also intend to rely on a variety of technologies that we will license from third parties, including any database and Internet server software, which will be used to operate our applications. These third-party licenses may not be available to us on commercially reasonable terms. The loss of or inability to obtain and maintain any of these licenses could delay the

Edgar Filing: I TRAX INC - Form 424B3

introduction of enhancements to our software applications, interactive tools and other features until equivalent technology could be licensed or developed. Any such delays could materially and adversely affect our business, results of operations and financial condition.

The loss of a major client will significantly reduce our revenues.

For the nine months ended September 30, 2004, we had one client, Goodyear, which accounted for 12% of our revenue. We anticipate that our results of operations in any given period will continue to be influenced to a certain extent by a relatively small number of clients. Accordingly, if we were to lose the business of such a client, our results of operations could be materially and adversely affected.

Risk Related to Our Industry

The healthcare industry is subject to general cost pressures that could reduce our revenue and gross margins.

The healthcare industry is currently under pressure by governmental and private-sector revenue sources to cut spiraling costs. These pressures will continue and possibly intensify. Although we believe that our services and software applications assist public health agencies, hospitals, health plans and self-insured employers to control the high costs associated with treating patients, the pressures to reduce costs immediately may hinder our ability (or increase the length of time we require) to obtain new contracts. In addition, the focus on cost reduction may pressure our customers to restructure contracts and reduce our fees.

We are affected by changes in the laws governing health plan, hospital and public health agency reimbursement under governmental programs such as Medicare and Medicaid. There are periodic legislative and regulatory initiatives to reduce the funding of the Medicare and Medicaid programs in an effort to curtail or reduce overall Federal healthcare spending. Federal legislation has and may continue to significantly reduce Medicare and Medicaid reimbursements to most hospitals. These reimbursement changes are negatively affecting hospital revenues and operations. Such legislative initiatives or government regulations could reduce demand for our services, our revenue and gross margins.

-14-

We are subject to judicial and statutory prohibitions on the corporate practice of medicine, and failure to comply with these prohibitions will expose us to heightened scrutiny by regulatory agencies, fines, litigation and possibly loss of revenue.

There are judicial and statutory prohibitions on the corporate practice of medicine, which vary from state to state. The corporate practice of medicine doctrine prohibits a corporation, other than a professional corporation, from practicing medicine or employing physicians. Some states also prohibit a non-physician from splitting or sharing fees charged by a physician for medical services. The services we provide include establishing and managing medical clinics. Most physician services at clinics we manage are provided by physicians who are employees of professional corporations with which we contract to provide non-professional services such as purchasing equipment and supplies, patient scheduling, billing, collection, accounting, and computer services. The professional corporations control hiring and supervise physicians and all medical functions. We have option agreements with the physician-owners of these affiliated professional corporations that entitle us to require the physician-owners to sell the stock of the professional corporations to any

Edgar Filing: I TRAX INC - Form 424B3

licensed physician we designate. This structure is intended to permit consolidation of the professional corporations' financial statements with ours, while maintaining sufficient separation to comply with the corporate practice of medicine doctrine and with fee-splitting and fee-sharing prohibitions. There remains, however, potential exposure to claims that this structure violates the corporate practice of medicine doctrine or fee-splitting or fee-sharing prohibitions, even though we do not believe that it does. If such a claim is successfully asserted against us in any jurisdiction, we could be subject to civil and criminal penalties, or could be required to restructure our contractual arrangements with clients. Any restructuring of contractual arrangements could result in lower revenues, increased expenses and reduced influence over the business decisions of those operations. Alternatively, some existing CHD Meridian Healthcare contracts could be found to be illegal and unenforceable, which could result in their termination and an associated loss of revenue, or inability to enforce valuable provisions of those contracts.

We have custody of confidential patient records and if we fail to comply with regulations applicable to maintaining such records we may be fined or sued.

Our personnel who staff our on-site pharmacies and clinics have custody of confidential patient records. Also, the computer servers we use to store our software applications and deliver our technology services also contain confidential health risk assessments completed by employees, patients and beneficiaries of our clients. In our capacity as a covered entity or as a business associate of a covered entity, we and the records we hold are subject to a rule entitled Privacy of Individually Identifiable Health Information, or Privacy Rule, promulgated by the U.S. Department of Health and Human Services under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and also to any state laws that may have more stringent privacy requirements. We attempt to protect the privacy and security of confidential patient information in accordance with applicable law, but could face claims of violation of the Privacy Rule, invasion of privacy or similar claims, if our patient records or computer servers were compromised, or if our interpretation of the applicable privacy requirements, many of which are complex, were incorrect or allegedly incorrect, or if we failed to maintain a sufficiently effective compliance program.

Furthermore, while we believe that the Privacy Rule protects our ability to obtain patient identifiable medical information for disease management purposes from certain of our clients, state legislation or regulations will preempt Federal legislation if state legislation or regulations are more restrictive. Accordingly, new Federal or state legislation or regulations restricting the availability of this information for disease management purposes could prevent us from performing services for our existing clients, termination of our disease management contracts and loss of revenue.

We are subject to fraud and abuse statutes because we bill the Medicare and Medicaid programs to recover amounts that offset the healthcare costs of our clients and if we violate such statutes, we will be subject to civil and criminal penalties.

In recent years, various government entities have actively investigated potential violations of fraud and abuse statutes and regulations by healthcare providers and by pharmaceutical manufacturers. The fraud and abuse provisions of the Social Security Act provide civil and criminal penalties and potential exclusion from the Medicare and Medicaid programs for persons or businesses who offer, pay, solicit or receive remuneration in order to induce referrals of patients covered by Federal healthcare programs (which include Medicare, Medicaid, TriCare and other

Federally funded health programs). Although our services and those of our affiliated professional corporations are generally paid for by employer clients, we do bill the Medicare and Medicaid programs, and private insurance companies, as agent of our affiliated professional corporations, to recover reimbursable amounts that offset the healthcare costs borne by our clients. We are therefore subject to various regulations under the Medicare and Medicaid programs, including fraud and abuse prohibitions. We believe that we are compliant with these requirements, but could face claims of non-compliance if our interpretations of the applicable requirements, many of which are complex, were incorrect or allegedly incorrect, or if we fail to maintain a sufficiently effective compliance program.

The professionals that staff our affiliated professional corporations as well as those we employ are subject to state and Federal licensure requirements and if we fail to comply with such licensure requirements, we may be scrutinized by regulatory agencies and fined.

The doctors, nurses and other healthcare professionals that staff our affiliated professional corporations, the nurses that staff our care communication centers, and our on-site pharmacies and clinics, are subject to individual licensing requirements. All of our healthcare professionals and facilities that are subject to licensing requirements are licensed in the state in which they are physically present. Multiple state licensing requirements for healthcare professionals who provide services telephonically over state lines may require us to license some of our healthcare professionals in more than one state. We continually monitor the developments in telemedicine. There is no assurance, however, that new judicial decisions or Federal or state legislation or regulations would not increase the requirement for multi-state licensing of all central operating unit call center health professionals, which would significantly increase our administrative costs. Further, in the event a state regulatory agency alleges that we do not comply with relevant licensing requirements, we may be subject to fines and administrative action.

The recently adopted Medicare prescription drug benefit legislation could reduce the demand for the prescription drug benefits we provide.

In December 2003, President Bush signed into law the Medicare Prescription Drug, Improvement and Modernization Act of 2003. This law provides Medicare beneficiaries with insurance coverage that offers access to prescription medicines. The prescription drug benefit, which will be called Medicare Part D, begins January 1, 2006. In the interim, a national prescription drug discount card for Medicare-eligible seniors will be instituted in April 2004. Under the new law, drug benefits will be provided through risk-bearing private plans contracting with the government (including plans offering only the Medicare Part D coverage as well as integrated plans offering all Medicare benefits). There will be an annual open period during which Medicare beneficiaries will choose their drug plan from among those available in their area of residence. In any areas where there are fewer than two private plan choices, the government will make a drug plan available directly.

We do not know how this law will affect our business. Subsidies for employers providing retiree drug benefits will decrease the costs to those employers of providing such benefits, and therefore may increase the number of employers willing to provide retiree drug benefits, which would positively affect our business. On the other hand, employers that now offer prescription drug benefits may decide no longer to do so, on the basis that their retirees now will be able to obtain such benefits on their own through Medicare. In that case, such employers would have less need for employer-dedicated pharmacies of the kinds that we establish and manage and reduce our revenue.

Edgar Filing: I TRAX INC - Form 424B3

Investment Risks

The price of our common stock is volatile and investors may lose money if they invest in our stock.

Our stock price has been and we believe will continue to be volatile. For example, from November 1, 2002 through November 26, 2004, the per share price of our stock has fluctuated from a high of \$5.70 to a low of \$1.37. The stock's volatility may be influenced by the market's perceptions of the healthcare sector in general, or other companies believed to be similar to us or by the market's perception of our operations and future prospects. Many of these perceptions are beyond our control. In addition, our stock is not heavily traded and therefore the ability to achieve relatively quick liquidity without a negative impact on our stock price is limited.

-16-

Some of our outstanding shares are restricted from immediate resale but may be sold into the market in the immediate future, which would cause the market price of our common stock to drop significantly, even if our business is doing well.

As of November 26, 2004, 28,655,871 shares of our common stock were issued and outstanding. Of this number, approximately 14,000,000 shares were issued in the CHD Meridian Healthcare merger as "restricted securities." Further, an additional 12,000,000 shares of our common stock, which are not reflected as issued and outstanding, are issuable upon conversion of our outstanding shares of Series A Convertible Preferred Stock. Of this latter amount, 2,000,000 shares are issuable upon conversion of Series A Convertible Preferred Stock issued in the CHD Meridian Healthcare merger and 10,000,000 shares are issuable upon conversion of Series A Convertible Preferred Stock sold to third party investors to fund a portion of the cash I-trax needed to acquire CHD Meridian Healthcare. This prospectus covers the resale of approximately 14,000,000 shares of our common stock and approximately 2,000,000 of the 12,000,000 shares of our common stock issuable upon conversion of our outstanding shares of Series A Convertible Preferred Stock issued or issuable in the CHD Meridian Healthcare merger. A separate prospectus covers the resale of the approximately 10,000,000 shares of our common stock issuable upon conversion of Series A Convertible Preferred Stock issued in the related financing. The two prospectuses cover an aggregate of approximately 26,000,000 shares of our common stock. If the selling shareholders under these prospectuses sell these shares at the same time, the market price of our common stock would most likely decline, possibly significantly.

Shares reserved for future issuance upon the conversion of outstanding shares of Series A Convertible Preferred Stock and upon the exercise of issued options and warrants may cause dilution.

As of November 26, 2004, approximately 12,000,000 shares of our common stock were reserved for issuance upon conversion of outstanding shares of Series A Convertible Preferred Stock and 7,010,561 shares of our common stock were reserved for issuance upon the exercise of our outstanding warrants and options. In addition, outstanding shares of our Series A Convertible Preferred Stock accrue dividend at the rate of 8% per year, which may be payable in common stock

Edgar Filing: I TRAX INC - Form 424B3

when shares of our Series A Convertible Preferred Stock are converted. Our stockholders, therefore, could experience dilution of their investment upon conversion or exercise, as applicable, of these securities.

Provisions of our certificate of incorporation could impede a takeover of our company, even though a takeover may benefit our stockholders, or delay or prevent a change in management.

Our board of directors has the authority, without further action by the stockholders, to issue from time to time, shares of preferred stock in one or more classes or series, and to fix the rights and preferences of such preferred stock, subject, however, to the limitations contained in the certificate of designations filed with respect to our Series A convertible preferred stock. We are subject to provisions of Delaware corporate law which, subject to certain exceptions, prohibit us from engaging in any "business combination" with a person who, together with affiliates and associates, owns 15% or more of our common stock (referred to as an interested stockholder) for a period of three years following the date that such person became an interested stockholder, unless the business combination is approved in a prescribed manner. Additionally, bylaws establish an advance notice procedure for stockholder proposals and for nominating candidates for election as directors. These provisions of Delaware law and of our certificate of incorporation and bylaws may have the effect of delaying, deterring or preventing a change in our existing management or control, may discourage bids for our common stock at a premium over market price and may adversely affect the market price, and the voting and other rights of the holders of our common stock.

-17-

STATEMENT REGARDING FORWARD LOOKING INFORMATION

This prospectus and our filings with the Securities and Exchange Commission, or SEC, incorporated by reference in this prospectus include forward-looking statements. All statements, other than statements of historical facts, included in this prospectus and our filings with the SEC incorporated by reference in this prospectus regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included or incorporated in this prospectus, particularly under the heading "Risk Factors" beginning on page 8 above, that we believe could cause actual results or events to differ materially from the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

CAUTIONARY NOTE

You should rely only on the information contained and incorporated by reference in this prospectus. No one has been authorized to provide you with different information. This prospectus is not an offer of these securities in

Edgar Filing: I TRAX INC - Form 424B3

any state where the offer is not permitted. You should not assume that the information contained and incorporated by reference in this prospectus or in any prospectus supplement is accurate as of any date other than the date on the front of the document.

-18-

MARKET FOR OUR COMMON STOCK

Our common stock trades on the American Stock Exchange under the symbol "DMX." Prior to January 15, 2003, our common stock was quoted on the Over-the-Counter Bulletin Board under the symbol "IMTX" and "ITRX." The following table sets forth the high and low closing prices for our common stock for the periods indicated. All closing prices have been adjusted to reflect a 1-for-5 reverse stock split effected as of close of business on January 3, 2003.

	High	Low
	----	---
2004		
Fourth Quarter (through November 26)	\$ 2.750	\$ 1.420
Third Quarter	\$ 4.290	\$ 2.600
Second Quarter	\$ 5.600	\$ 3.290
First Quarter	5.700	3.910
2003		
Fourth Quarter	4.490	2.600
Third Quarter	3.790	2.600
Second Quarter	3.000	1.510
First Quarter	5.000	1.370
2002		
Fourth Quarter	4.300	2.500
Third Quarter	5.100	2.750

As of November 26, 2004, there were approximately 419 registered holders of our common stock and approximately 70 registered holders of our Series A Convertible Preferred Stock. On November 26, 2004, the last reported sales price of our common stock was \$1.42.

Dividend Policy

We have never paid or declared any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future.

Our Series A Convertible Preferred Stock accrues dividends on the original issue price at the rate of 8% per annum. The dividends are payable upon conversion of Series A Convertible Preferred Stock into common stock in additional shares of common stock or, subject to the consent of our senior secured lender, in cash.

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of shares of our common stock offered under this prospectus.

Edgar Filing: I TRAX INC - Form 424B3

-19-

SELLING SECURITY HOLDERS

We are registering for offer and sale by the applicable holders:

- o up to 13,851,550 shares of our common stock; and
- o up to 1,998,886 shares of our common stock issuable upon the conversion of outstanding Series A Convertible Preferred Stock.

Based on information provided to us by the selling shareholders, the following table sets forth ownership regarding the shares held by the selling shareholders.

Name of Selling Shareholder	Number of Shares of Common Stock Owned Before Offering (1)		Number of Shares of Common Stock Offered
	Common Stock	Common Stock underlying preferred stock	
Warburg, Pincus Ventures L.P.	4,148,461	623,595	4,148,461
Centre Reinsurance Limited	2,329,174	336,119	2,329,174
CHD Investors LLC	1,544,646	232,190	1,544,646
Michael J. Hardies	1,472,369	221,326	1,472,369
Susan M. Mathews	1,470,995	213,591	1,470,995
Finn Iverson Mathews, Colin Mathews Custodian	2,277	--	2,277
Beck Andrew Mathews, Colin Mathews Custodian	2,277	--	2,277
Nora Keller Mathews, Brendan Mathews Custodian	2,277	--	2,277
Quinn Annaley Mathews, Devin Mathews Custodian	2,277	--	2,277
Franklin Capital Associates III L.P.	925,567	139,131	925,567
Pacific Venture Group, L.P.	651,209	93,974	651,209
Bessemer Venture Partners MOHA	431,958	64,931	431,958
Charles D. Phillips	376,389	16,837	376,389
Coleman Swenson Hoffman Booth IV L.P.	219,324	32,968	219,324
Haywood D. Cochrane, Jr.	154,109	6,893	154,109
PVG Associates, L.P.	30,526	4,405	30,526
Stryker Warren Jr.	29,858	4,338	28,858
John H. Austin	16,351	2,359	16,351
CGJR Health Care Services Private Equities, L.P.	16,265	2,445	16,265
Craig Macnab	12,857	1,855	12,857
Jim Baker	4,088	589	4,088
Perry W. Moskovitz	4,088	589	4,088
Stuart Smith	2,967	428	2,967
Donald I.N. McKenzie	2,241	323	2,241

Edgar Filing: I TRAX INC - Form 424B3

- (1) The actual number of shares of common stock offered in this prospectus and included in the registration statement of which this prospectus is a part includes such additional number of shares of common stock as may be issued or issuable by reason of any stock split, stock dividend or similar transaction involving the common stock, in accordance with Rule 416 under the Securities Act of 1933, as amended, or Securities Act.

-20-

* Less than 1%.

Material Relationships and Transactions

The 13,851,550 shares of common stock offered for resale under this prospectus were issued as part of an aggregate of 13,859,200 shares issued in connection with I-trax's acquisition of CHD Meridian Healthcare. Of this amount, 10,000,000 shares of common stock were issued to the selling shareholders and 3,859,200 were issued to an escrow agent for the benefit of the selling shareholders.

An aggregate of 1,998,886 shares of common stock offered for resale under this prospectus are issuable upon conversion of Series A Convertible Preferred Stock. I-trax issued 200,000 shares of Series A Convertible Preferred Stock to the former stockholders of CHD Meridian Healthcare in connection with I-trax's acquisition of CHD Meridian Healthcare. Each share of Series A Convertible Preferred Stock is convertible into 10 shares of common stock at the conversion price of \$2.50 per share. Series A Convertible Preferred Stock also accrues dividends on the original issue price of \$25 per share at the rate of 8% per annum. The dividends are payable upon conversion of the Series A Convertible Preferred Stock into common stock in additional shares of common stock or, subject to the consent of our senior secured lender, in cash.

We are registering for resale the shares of common stock and the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock offered for resale under this prospectus because we are required to do so by the merger agreement between I-trax and CHD Meridian Healthcare.

Haywood D. Cochrane, Jr. is a director and vice chairman of I-trax, and prior to the acquisition of CHD Meridian Healthcare by I-trax served as chief executive officer of CHD Meridian Healthcare.

Charles D. ("Chip") Phillips is executive vice president and chief operating officer of I-trax, and prior to the acquisition of CHD Meridian Healthcare by I-trax served as a director and chief operating officer of CHD Meridian Healthcare.

Michael J. Hardies, M.D., is a senior vice president and chief medical officer - emeritus of I-trax and prior to the acquisition of CHD Meridian Healthcare by I-trax served as chairman and chief medical officer of CHD Meridian Healthcare.

Eileen Sweeney, a former officer and director of certain entities affiliated with Centre Reinsurance Limited, served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

W. David Swenson, an affiliate of Franklin Capital Associates III L.P. and Coleman Swenson Hoffman Booth IV L.P., served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

Edgar Filing: I TRAX INC - Form 424B3

Joel Ackerman, a representative of Warburg, Pincus Ventures L.P., served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

Brad Cooper, a representative of CHD Investors, LLC, served as a director of CHD Meridian Healthcare prior to its acquisition by I-trax.

-21-

Voting and Dispositive Power

The following individuals have voting and dispositive power with respect to the shares of I-trax common stock offered under this prospectus for resale by entities:

Name of Selling Shareholder	Individual or Individuals Who Exercise Dispositive Power
-----	-----
Warburg, Pincus Ventures L.P.	Warburg, Pincus and Co., the general partner of Warburg Pincus LLC, manager
Centre Reinsurance Limited	Philip Thorne, Stephen Williams or Emory
CHD Investors LLC	The ultimate corporate general partner of CHD Investors LLC and dispositive power.
Franklin Capital Associates III L.P.	W. David Swenson
Pacific Venture Group, L.P. and PVG Associates, L.P.	Layton R. Crouch, or any other active general partner of Pacific Venture Group, L.P. and PVG Associates, L.P.
Bessemer Venture Partners MOHA	Bessemer Venture Partners III L.P., a partnership, serves as the Managing Partner of Bessemer Venture Partners MOHA and has voting and dispositive power over the shares of I-trax common stock offered by Bessemer Venture Partners MOHA. A partnership agreement between William T. Burgin, Rober H. Buescher, Christopher F.O. Gabrieli and David Cowan, who are the managing members of Bessemer Venture Partners MOHA LLC, the general partner of Bessemer Venture Partners III L.P., share voting and dispositive power over the shares of I-trax common stock offered prospectus by Bessemer Venture Partners MOHA. The individuals disclaim beneficial ownership of the shares held by Bessemer Venture Partners MOHA covered by the registration statement and the prospectus is a part except to the extent of their pecuniary interest in such shares.
Coleman Swenson Hoffman Booth IV L.P.	W. David Swenson
CGJR Health Care Services Private Equities, L.P.	Christopher Grant, Jr., president of CGJR Health Care Services Private Equities Management, Inc., the general partner of CGJR Health Care Series Private Equities, L.P.

-22-

Edgar Filing: I TRAX INC - Form 424B3

PLAN OF DISTRIBUTION

Subject to certain limitations on sales or other transfers agreed to by us and certain of the selling shareholders that are described below, the shares being offered by the selling shareholders or their respective pledgees, donees, transferees or other successors in interest, may be sold from time to time in one or more transactions, which may involve block transactions:

- o on the American Stock Exchange or on such other market on which the common stock may from time to time be trading;
- o in privately-negotiated transactions;
- o through broker-dealers, who may act as agents or principals;
- o through one or more underwriters on a firm commitment or best efforts basis;
- o through the writing of options on the shares;
- o to cover short sales and other hedging transactions made after the date that the registration statement of which this prospectus is a part was declared effective by the SEC; or
- o any combination thereof.

The sale price to the public may be:

- o the market price prevailing at the time of sale;
- o a price related to such prevailing market price;
- o at negotiated prices; or
- o such other price as the selling shareholders determine from time to time.

The shares may also be sold pursuant to Rule 144 under the Securities Act, as permitted by that rule. The selling shareholders shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if they deem the purchase price to be unsatisfactory at any particular time.

The selling shareholders or their respective pledgees, donees, transferees or other successors in interest may also sell the shares directly to market makers acting as principals or broker-dealers acting as agents for themselves or their customers. These broker-dealers may be compensated with discounts, concessions or commissions from the selling shareholders or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal or both. The compensation as to a particular broker-dealer might be greater than customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. The selling shareholders may sell shares of common stock in block transactions to market makers or other purchasers at a price per share, which may be below the then market price.

The selling shareholders cannot assure that all or any of the shares offered in this prospectus will be issued to, or sold by, the selling shareholders.

Haywood D. Cochrane, Jr. and Charles D. Phillips have agreed that during the period beginning on the date of this prospectus and ending 90 days after such date, they will not, without the prior written consent of the

Edgar Filing: I TRAX INC - Form 424B3

majority of our independent directors, directly or indirectly, sell, offer to sell, contract to sell, loan, pledge, grant any option for sale or purchase of, agree to sell or otherwise dispose of, any shares of our common stock, or any securities convertible into or exercisable for our

-23-

common stock, they beneficially own or may acquire, or with respect to which the they now have or may acquire the power of disposition.

Subject to the exceptions described in the following paragraph, Warburg, Pincus Ventures L.P., Centre Reinsurance Limited, CHD Investors LLC, Michael J. Hardies, Susan M. Mathews, Franklin Capital Associates III L.P., Pacific Venture Group, L.P., Bessemer Venture Partners MOHA, Coleman Swenson Hoffman Booth IV L.P. and PVG Associates, L.P. have agreed that during the period prior to December 1, 2004, they will not, directly or indirectly, issue, sell, offer or agree to sell, grant any option for the sale of, pledge, make any short sale or maintain any short position, establish or maintain a "put equivalent position" (within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, or Exchange Act), enter into any swap, derivative transaction or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the shares of common stock (whether any such transaction is to be settled by delivery of shares of common stock, other securities, cash or other consideration), or otherwise dispose of, any shares of common stock (or any securities convertible into, exercisable for or exchangeable for shares of common stock) or interest therein of us or of any of our subsidiaries.

Warburg, Pincus Ventures L.P., Centre Reinsurance Limited, CHD Investors LLC, Michael J. Hardies, Susan M. Mathews, Franklin Capital Associates III L.P., Pacific Venture Group, L.P., Bessemer Venture Partners MOHA, Coleman Swenson Hoffman Booth IV L.P. and PVG Associates, L.P. have also agreed that at any time before December 1, 2004 they may only sell or otherwise transfer any shares of common stock offered under this prospectus with our prior written consent or through one or more underwriters or placement agents identified by us. In turn, we have agreed with these selling shareholders that to the extent we grant our written consent permitting any of them to sell or otherwise transfer any shares of common stock offered under this prospectus, we will do so for all of them to the same extent. We have also agreed with these selling shareholders that, during this period, we will use our reasonable commercial efforts to identify one or more underwriters or placement agents to place up to 25% of the shares offered by them under this prospectus. Once one or more underwriters or placement agents are identified, these selling shareholders may enter into an agreement or agreements with any such underwriters or placement agents. The relevant details of such agreement or agreements will be set forth in a supplement or revisions to this prospectus.

Subject to the limitations and arrangements described above, any selling shareholder may, at any time, sell all or any part of the shares offered in this prospectus through an underwriter. No selling stockholder has entered into any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered into. If a selling shareholder enters into such an agreement or agreements, the relevant details will be set forth in a supplement or revisions to this prospectus.

Because the selling shareholders and any brokers, dealers or agents, upon effecting the sale of any of the shares offered in this prospectus, may potentially be deemed "underwriters" as that term is defined under the Securities Act, the Exchange Act, or the rules and regulations under such acts, the selling shareholders will be subject to the prospectus delivery requirements

Edgar Filing: I TRAX INC - Form 424B3

of the Securities Act. Any commissions received by them and any profit on the resale of shares may be deemed to be underwriting compensation.

The shares will be sold through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states the shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

The selling shareholders and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Exchange Act and the rules and regulations under the Exchange Act, including, without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of any of the shares by, the selling shareholders or any other such person. Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period of time prior to the commencement of such distributions, subject to specified exceptions or exemptions. All of these limitations may affect the marketability of the shares.

-24-

We will bear all costs, expenses and fees in connection with the registration of the shares. The selling shareholders will bear all commissions and discounts, if any, attributable to the sales of the shares. The selling shareholders may agree to indemnify any broker-dealer or agent that participates in transactions involving sales of the shares against certain liabilities, including liabilities arising under the Securities Act.

AVAILABLE INFORMATION

We file reports, proxy statements and other information with the SEC (File No. 001-31584). Copies of these reports, proxy statements and other information may be inspected and copied at the public reference facilities maintained by the SEC at Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies of these materials can also be obtained by mail at prescribed rates from the Public Reference Section of the SEC, 450 Fifth Street, N.W., Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding our company. The address of this website is <http://www.sec.gov>.

We have filed a registration statement on Form S-3 under the Securities Act with the SEC with respect to the shares of our common stock covered by this prospectus. This document constitutes the prospectus of I-trax filed as part of that registration statement. This document does not contain all of the information set forth in the registration statement because some parts of the registration statement are omitted as provided by the rules and regulations of the SEC. You may inspect and copy the registration statement at any of the addresses listed above.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

Edgar Filing: I TRAX INC - Form 424B3

The following documents we have filed with the SEC (File No. 001-31584) pursuant to the Exchange Act are incorporated herein by reference:

- o our Annual Report on Form 10-KSB for the year ended December 31, 2003, filed on April 8, 2004, as amended by Form 10-KSB/A filed on June 2, 2004 and by Form 10-KSB/A filed on August 11, 2004;
- o our Quarterly Report on Form 10-QSB for the quarter ended March 31, 2004, filed on May 14, 2004, as amended by Form 10-QSB/A filed on August 11, 2004 and by Form 10-QSB/A filed on November 10, 2004, our Quarterly Report on Form 10-QSB for the quarter ended June 30, 2004 filed on August 18, 2004, as amended by Form 10-QSB/A filed on November 10, 2004, and our Quarterly Report on Form 10-QSB for the quarter ended September 30, 2004 filed on November 15, 2004;
- o our Current Report on Form 8-K filed on March 30, 2004, as amended by Form 8-K/A filed on June 2, 2004, by Form 8-K/A filed on August 11, 2004 and by Form 8-K/A filed on November 10, 2004, and our Current Report on Form 8-K filed on November 22, 2004;
- o the description of our common stock, \$0.001 par value per share, and associated rights, contained in our registration statement on Form 8-A, filed on January 14, 2003, including any amendment or report filed for the purpose of updating this description; and
- o all reports and other documents filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this prospectus and prior to the termination of the offering.

Any statement contained in a document incorporated by reference in this prospectus will be deemed to be incorporated by reference in this prospectus and to be part of this prospectus from the date of filing of the document. Any statement modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We will provide upon written or oral request without charge to each person to whom this prospectus is delivered a copy of any or all of the documents which are incorporated in this prospectus by reference (other than exhibits to those documents unless those exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). Written requests for copies should be directed to I-trax, Inc., Investor Relations, 4 Hillman Drive, Suite 130, Chadds Ford, Pennsylvania 19317. Our telephone number is (610) 459-2405.

-25-

LEGAL MATTERS

The validity of the shares of our common stock offered by this prospectus will be passed upon for us by our Vice President, General Counsel and Secretary.

Edgar Filing: I TRAX INC - Form 424B3

EXPERTS

The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-KSB/A of I-trax, Inc. for the year ended December 31, 2003 and for each of the two years in the period then ended have been so incorporated in reliance on the reports of Goldstein Golub Kessler LLP, independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

The financial statements of CHD Meridian Healthcare at December 31, 2003 and 2002, and for each of the three years in the period ended December 31, 2003, incorporated in this prospectus by reference to the Current Report on Form 8-K/A of I-trax, Inc. filed on November 10, 2004 have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

-26-

=====

5,043,177 SHARES

I-TRAX

[LOGO OMITTED]

COMMON STOCK

PROSPECTUS SUPPLEMENT

OPPENHEIMER & CO.

DECEMBER 17, 2004
